Skip to main content

Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis

Clinical and Experimental Nephrology volume 17, pages 405–410 (2013)Cite this article

Abstract

Background

Anti-centromere antibody (ACA), a typical autoantibody of systemic sclerosis, is also detected in primary biliary cirrhosis (PBC). However, its pathogenic role is not fully understood. The aim of this study was to determine the association between ACA and kidney function in PBC.

Methods

A cohort of 37 patients diagnosed as having PBC from July 2001 to November 2011 at Yokosuka Kyosai Hospital was retrospectively analyzed for a follow-up period of 12 months. The annual rate of estimated glomerular filtration rate (eGFR) decline within 1 year after the diagnosis was evaluated. The factors associated with eGFR decline were evaluated by linear regression analysis and logistic regression analysis.

Results

Overall, 37 PBC patients were included, of whom 12 (32 %) had ACA. The patients with ACA had a lower eGFR (65.9 ± 19.9 vs. 80.3 ± 12.1 mL/min/1.73 m2, P = 0.01), a higher likelihood of chronic kidney disease (CKD) (58 vs. 4 %, P = 0.0005), and a higher rate of annual eGFR decline (−4.3 ± 5.1 vs. 0.2 ± 4.6 mL/min/year, P = 0.01) than those without ACA. Univariate regression analysis and multivariate regression analysis adjusted for potential cofounders including age, eGFR, sex, diabetes mellitus, and hypertension showed that ACA was associated with eGFR decline (P = 0.011 and 0.017, respectively). Multivariate logistic regression analysis adjusted for these cofounders showed that ACA was associated with eGFR decline less than −4 mL/min/year (odds ratio 7.21, 95 % confidence interval 0.93–56.1, P = 0.059).

Conclusions

ACA is an independent risk factor for CKD in PBC. Evaluation of ACA and kidney function is necessary to prevent CKD progression in PBC patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA. 1980;77:1627–31.

    PubMed  Article  CAS  Google Scholar 

  2. Zuber M, Gotzen R, Filler I. Clinical correlation of anticentromere antibodies. Clin Rheumatol. 1994;13:427–32.

    PubMed  Article  CAS  Google Scholar 

  3. Nakano M, Ohuchi Y, Hasegawa H, Kuroda T, Ito S, Gejyo F. Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. J Rheumatol. 2000;27:1403–7.

    PubMed  CAS  Google Scholar 

  4. Katano K, Kawano M, Koni I, Sugai S, Muro Y. Clinical and laboratory features of anticentromere antibody positive primary Sjogren’s syndrome. J Rheumatol. 2001;28:2238–44.

    PubMed  CAS  Google Scholar 

  5. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45:118–27.

    PubMed  Article  CAS  Google Scholar 

  6. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis. 2005;25:298–310.

    PubMed  Article  Google Scholar 

  7. Parveen S, Morshed SA, Nishioka M. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol. 1995;10:438–45.

    PubMed  Article  CAS  Google Scholar 

  8. Gliddon AE, Doré CJ, Dunphy J, Betteridge Z, McHugh NJ, QUINS Trial Study Group. Antinuclear antibodies and clinical associations in a british cohort with limited cutaneous systemic sclerosis. J Rheumatol. 2011;38:702–5.

    PubMed  Article  Google Scholar 

  9. Nguyen B, Mayes MD, Arnett FC, del Junco D, Reveille JD, Gonzalez EB, et al. HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis. Arthritis Rheum. 2011;63:530–4.

    PubMed  Article  Google Scholar 

  10. Mandai S, Arai Y, Hirasawa S, Hirai T, Aki S, Inaba N, et al. Anti-centromere antibody-positive subjects presenting with hypertensive emergency and renal dysfunction in the absence of skin manifestations: a variant of systemic sclerosis or a novel entity? Intern Med. 2012;51:1567–72.

    PubMed  Article  Google Scholar 

  11. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology. 2003;42:534–40.

    PubMed  Article  CAS  Google Scholar 

  12. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.

    PubMed  Article  Google Scholar 

  13. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med. 1967;60:1257–60.

    PubMed  CAS  Google Scholar 

  14. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al., Japanese Society of Hypertension Committee. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009;32:3–107.

    PubMed  CAS  Google Scholar 

  15. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc. 2010;53:450–67.

    Google Scholar 

  16. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

    PubMed  Article  CAS  Google Scholar 

  17. Shoji I, Takagi T, Kasukawa R. Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis. Intern Med. 1992;31:1348–55.

    PubMed  Article  CAS  Google Scholar 

  18. Hernandez NM, Casselbrant A, Joshi M, Johansson BR, Sumitran-Holgersson S. Antibodies to kidney endothelial cells contribute to a “leaky” glomerular barrier in patients with chronic kidney diseases. Am J Physiol Renal Physiol. 2012;302:884–94.

    Article  Google Scholar 

  19. Servettaz A, Tamby MC, Guilpain P, Reinbolt J, de la Garcia Penã-Lefebvre P, Allanore Y, et al. Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). Clin Immunol. 2006;120:212–9.

    PubMed  Article  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Affiliations

  1. Department of Nephrology, Yokosuka Kyosai Hospital, 1-16 Yonegahamadori, Yokosuka, Kanagawa, 238-8558, Japan

    Shintaro Mandai, Yohei Arai, Suguru Hirasawa, Toshiyuki Hirai, Shota Aki, Naoto Inaba, Makoto Aoyagi, Hiroyuki Tanaka & Teiichi Tamura

  2. Department of Nephrology, Tokyo Kyosai Hospital, Tokyo, Japan

    Eiichiro Kanda

  3. Department of Gastroenterology, Yokosuka Kyosai Hospital, Kanagawa, Japan

    Takaaki Ikeda

  4. Department of Nephrology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan

    Sei Sasaki

Authors
  1. Shintaro Mandai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eiichiro Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yohei Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suguru Hirasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshiyuki Hirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shota Aki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoto Inaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Makoto Aoyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroyuki Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takaaki Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Teiichi Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sei Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shintaro Mandai.

About this article

Cite this article

Mandai, S., Kanda, E., Arai, Y. et al. Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis. Clin Exp Nephrol 17, 405–410 (2013). https://doi.org/10.1007/s10157-012-0724-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-012-0724-1

Keywords

  • Anti-centromere antibody
  • Chronic kidney disease
  • Primary biliary cirrhosis
  • Systemic sclerosis